Ask AI
2025 SABCS MBC

CME

Decera Clinical Education Independent Conference Highlights of the San Antonio Breast Cancer Symposium 2025: Advanced and Metastatic Breast Cancer

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: February 20, 2026

Expiration: August 19, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Li H, Wu Y, Zou H, et al. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials. EBioMedicine. 2024;105:105186.
  2. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942-950.
  3. Neven P, Fasching PA, Chia S, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Res. 2023;25:103.
  4. Lu YS, Im SA, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2022;28:851-859.
  5. André F, Fasching PA, Prat A, et al. Pooled analysis of patients treated with 1st-line ribociclib + endocrine therapy in the MONALEESA studies: long-term progression-free survival. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract PD5-10.
  6. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:122-137.
  7. Gheysen M, Punie K, Wildiers H, Neven P. Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review. Cancer Treat Rev. 2024;130:102825.
  8. Elacestrant [prescribing information]. New York, NY: Stemline Therapeutics, Inc; 2023.
  9. Rugo HS, Tolaney SM, Chan N, et al. Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer: phase 2 results from ELEVATE, an open-label umbrella trial. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract RF7-01.
  10. Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase-3 EMBER-3 trial. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract GS3-08.
  11. Bidard FC. Circulating tumor DNA (ctDNA) dynamics from patients with ER+, HER2- advanced breast cancer in the phase 3 EMBER-3 trial. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract PD5-08.
  12. Imlunestrant [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2025.
  13. Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial. Ann Oncol. 2025:S0923-7534(25)06289-1
  14. Jhaveri KL, Neven P, Casalnuovo ML, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392:1189.
  15. Turner N, Huang-Bartlett C, Kalinsky K, et al. Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): phase 3, double-blind ctDNA-guided SERENA-6 trial. Presented at: 2025 American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2025. Abstract LBA4.
  16. Bidard FC, Mayer EL, Park YH, et al. Updated results and an exploratory analysis of ESR1m circulating tumor DNA dynamics from SERENA-6, a phase 3 trial of camizestrant + CDK4/6 inhibitor for emergent ESR1m during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2- advanced breast cancer. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract RF7-03.
  17. McCormick B, Brufsky A. Camizestrant-related photopsia mostly mild, nondisabling in patients with advanced breast cancer: Adam Brufsky, MD, PhD. AJMC. 2025. ajmc.com/view/camizestrant-related-photopsia-mostly-mild-nondisabling-in-patients-with-advanced-breast-cancer-adam-brufsky-md-phd. Accessed February 16, 2026.
  18. Cleveland clinic.org. Photopsias (eye flashes). my.clevelandclinic.org/health/symptoms/25069-photopsias-eye-flashes. Accessed February 16, 2026.
  19. Brufsky A. Visual functioning and characterization of visual effects from SERENA-6, a phase 3 study of switch to camizestrant from aromatase inhibitor while continuing CDK4/6 inhibitor at emergence of ESR1 mutations during first-line therapy for patients with HR+/HER2- advanced breast cancer. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract PD10-04.
  20. Mayer E, Tolaney SM, Martin M. Giredestrant (GIRE), an oral selective estrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): primary results of the phase III evERA BC trial. Presented at: European Society for Medical Oncology Congress 2025; October 17-21, 2025. Abstract LBA16.
  21. Rugo HS, Tolaney SM, Jhaveri KL, et al. Clinical and biomarker subgroup analysis of evERA breast cancer: a phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract GS3-09.
  22. National Cancer Institute. Tersolisib. cancer.gov/publications/dictionaries/cancer-drug/def/tersolisib. Accessed February 16, 2026.
  23. Glaherty C and Hollasch M. Novel PI3Kα inhibitor STX-478 offers precise treatment and reduced toxicity for solid tumors. OncLive. 2024. onclive.com/view/novel-pi3k-inhibitor-stx-478-offers-precise-treatment-and-reduced-toxicity-for-solid-tumors. Accessed February 16, 2026.
  24. Jhaveri K, Juric D, Giordano A, et al. A phase 1/2 trial of LY4064809 (STX-478), a pan-mutant-selective PI3Kα inhibitor in HR+, HER2- advanced breast cancer (ABC): updated results from PIKALO-1. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract PS1-08-24.
  25. Hamilton E, Curigliano G, Martin M, et al. HER2CLIMB-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer. J Clin Oncol. 2025;[Epub ahead of print].
  26. Tolaney SM, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): interim results from DESTINY-Breast09. Presented at: 60th Annual Meeting of the American Society of Clinical Oncology; May 30 - June 3, 2025. Abstract LBA1008.
  27. Metzger O, Mandrekar S, DeMichele A, et al. AFT-38 PATINA: a randomized, open-label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer. Presented at: San Antonio Breast Cancer Symposium 2024; December 10-13, 2025. Abstract GS2-12.
  28. Metzger O, Mandrekar S, Dockter T, et al. Central nervous system outcomes from the phase III PATINA trial (AFT-38). Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract RF4-01.
  29. Dieras V, Curigliano G, Martin M, et al. HER2CLIMB-05: a phase III study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer. J Clin Oncol. 2025;[Epub ahead of print].
  30. Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib pus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610-2619.
  31. Fam-trastuzumab deruxtecan-nxki [prescribing information). Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2025.
  32. Rimawi MF, Loibl S, Jiang Z, et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab (THP) for first-line treatment of patients with HER2+ advanced/metastatic breast cancer: patient-reported outcomes from the DESTINY-Breast09 study. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract RF6-07.
  33. Jhaveri K, Park YH, Barrios C, et al. Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2- (IHC 0, 1+, 2+/ISH-) metastatic breast cancer: primary results from ASCENT-07. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract GS1-09.
  34. Sacituzumab govitecan [prescribing information]. Foster City, CA: Gilead; 2025.
  35. Hurvitz S, Bardia A, Tolaney SM, et al. Safety analysis of ASCENT-03, a phase 3 study of sacituzumab govitecan vs chemotherapy for previously untreated advanced triple-negative breast cancer in patients who are not candidates for PD-(L)1 inhibitors. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract PS1-13-24.
  36. Cortés J, Bardia A, Punie K, et al. Primary results from ASCENT-03: a randomized phase 3 study of sacituzumab govitecan vs chemotherapy in patients with previously untreated metastatic triple-negative breast cancer who are unable to receive PD-(L)1 inhibitors. Presented at: European Society for Medical Oncology Congress 2025; October 17-21, 2025. Abstract LBA20.
  37. Cortés J, Punie K, Barrios C, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med. 2025;393:1912-1925.
  38. Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1 positive, advanced or metastatic triple-negative breast cancer: primary results from the randomized, phase 3 ASCENT-04/KEYNOTE-D19 study. Presented at: 2025 American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2025. Abstract LBA109.
  39. Kalinsky K, Schmid P, de Azambuja E, et al. Safety analysis of phase 3 ASCENT-04 study of sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab for previously untreated PD-L1+ metastatic triple-negative breast cancer. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract PS5-02-28.
  40. Dent RA, Shao Z, Schmid P, et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. Presented at: European Society for Medical Oncology Congress 2025; October 17-21, 2025. Abstract LBA21.
  41. Schmid P, Shao Z, et al. First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: additional safety data from the TROPION-Breast02 study. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract PS5-03-05.
  42. Tarantino P, Zhou N, Li T, et al. Intracranial activity of datopotamab deruxtecan (Dato-DXd) for patients with HER2-negative breast cancer and leptomeningeal disease (LMD): results from cohort C of the DATO-Base phase 2 trial. Presented at: San Antonio Breast Cancer Symposium 2025; December 19-12, 2025. Abstract PS1-09-20.